pomalidomide has been researched along with Immunoglobulin Light-chain Amyloidosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basset, M; Foli, A; Hegenbart, U; Kimmich, C; Mahmood, S; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Sachchithanantham, S; Schönland, SO; Sharpley, F; Wechalekar, A | 1 |
| Chakraborty, R; Lentzsch, S | 1 |
| Joseph, NS; Kaufman, JL | 1 |
| Gilmore, J; Hawkins, P; Lachmann, H; Mahmood, S; Manwani, R; Sachchithanantham, S; Sharpley, FA; Wechalekar, A; Whelan, C | 1 |
| Adamu, H; Arnall, JR; Bhutani, M; Mishkin, J; Usmani, SZ | 1 |
2 review(s) available for pomalidomide and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Emerging drugs for the treatment of light chain amyloidosis.
Topics: Animals; Antibodies, Monoclonal; Bridged Bicyclo Compounds, Heterocyclic; Drug Development; Humans; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Sulfonamides; Thalidomide | 2020 |
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Magnetic Resonance Imaging; Prognosis; Thalidomide | 2018 |
1 trial(s) available for pomalidomide and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Thalidomide | 2018 |
2 other study(ies) available for pomalidomide and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Topics: Aged; Anti-Inflammatory Agents; Dexamethasone; Drug Resistance; Europe; Female; Follow-Up Studies; Hematologic Tests; Humans; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2020 |
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |